Ning Xi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ning Xi has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
Marco A. Ciufolini
Lab. Synth. Methodol. Org., Ec. Super. Chim., Phys., Electron. Lyon, Univ. Claude Bernard Lyon, F-69622 Villeurbanne, Fr
10 shared publicationsMingming Sun
College of Chemistry and Chemical Engineering
8 shared publicationsCelia Dominguez
7 shared publicationsDelphine Valognes
Lab. Synth. Methodol. Org., Ec. Super. Chim., Phys., Electron. Lyon, Univ. Claude Bernard Lyon, F-69622 Villeurbanne, Fr
7 shared publicationsMark H. Norman
Departments of Medicinal Chemistry, ‡Oncology Research, and §Molecular Structure, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
7 shared publicationsShimin Xu
Departments of Medicinal Chemistry, Molecular Structure, Oncology Research, Pharmaceutics, and Pharmacokinetics and Drug Metabolism, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799
7 shared publications
Latest Publications
- 23 July 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 9351-9423
From reagents to feedstocks: reprogramming heteroatom-containing molecules in modern organic synthesis
- 23 July 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 9351-9423
From reagents to feedstocks: reprogramming heteroatom-containing molecules in modern organic synthesis
- 11 July 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 9525-9557
Nitrogen atom insertion and related skeletal editing strategies in aromatic heterocycles for drug discovery (2015–2025)
Nitrogen-containing heterocycles constitute the pharmacophoric core of the majority of clinically approved small-molecule drugs, yet their conventional synthesis relies on scaffold-specific condensation routes that are poorly suited to late-stage structural diversification. The emergence of single-atom skeletal editing, where one nitrogen atom is inserted directly into an intact aromatic ring to transform scaffold identity without rebuilding the molecular periphery, represents a fundamental departure from traditional heterocycle synthesis and provides a powerful new retrosynthetic logic for medicinal chemistry. This review surveys significant advances in nitrogen atom insertion into aromatic N-heterocycles reported between 2015 and 2025, organized by mechanistic platform. We discuss nitrene-mediated insertion using iodonitrene and sulfenylnitrene reagents, transition-metal-catalysed strategies including copper- and cobalt-catalysed ring expansions and carbon-to-nitrogen transmutation of arenols, electrochemical approaches that eliminate stoichiometric oxidants, and emerging photochemical and photolytic methods that enable late-stage modification of complex substrates. For each platform, substrate scope, functional group tolerance, mechanistic underpinning, and practical limitations are critically evaluated. We further highlight how these strategies collectively enable nitrogen scanning in drug discovery, the systematic replacement of carbon with nitrogen within a lead scaffold to modulate potency, selectivity, and pharmacokinetic properties. Key open challenges including enantioselective nitrogen insertion, predictive regioselectivity, and scalable sustainable synthesis are outlined alongside future directions for this rapidly evolving field.
- 11 July 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 9525-9557
Nitrogen atom insertion and related skeletal editing strategies in aromatic heterocycles for drug discovery (2015–2025)
Nitrogen-containing heterocycles constitute the pharmacophoric core of the majority of clinically approved small-molecule drugs, yet their conventional synthesis relies on scaffold-specific condensation routes that are poorly suited to late-stage structural diversification. The emergence of single-atom skeletal editing, where one nitrogen atom is inserted directly into an intact aromatic ring to transform scaffold identity without rebuilding the molecular periphery, represents a fundamental departure from traditional heterocycle synthesis and provides a powerful new retrosynthetic logic for medicinal chemistry. This review surveys significant advances in nitrogen atom insertion into aromatic N-heterocycles reported between 2015 and 2025, organized by mechanistic platform. We discuss nitrene-mediated insertion using iodonitrene and sulfenylnitrene reagents, transition-metal-catalysed strategies including copper- and cobalt-catalysed ring expansions and carbon-to-nitrogen transmutation of arenols, electrochemical approaches that eliminate stoichiometric oxidants, and emerging photochemical and photolytic methods that enable late-stage modification of complex substrates. For each platform, substrate scope, functional group tolerance, mechanistic underpinning, and practical limitations are critically evaluated. We further highlight how these strategies collectively enable nitrogen scanning in drug discovery, the systematic replacement of carbon with nitrogen within a lead scaffold to modulate potency, selectivity, and pharmacokinetic properties. Key open challenges including enantioselective nitrogen insertion, predictive regioselectivity, and scalable sustainable synthesis are outlined alongside future directions for this rapidly evolving field.
- Open Access
- 3 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (23) , 34786-34807
Structure-Based Drug Discovery of Triazine Derivatives as Potent and Orally Bioavailable AXL Inhibitors for Cancer Therapy
The receptor tyrosine kinase AXL is overexpressed in various cancers. There is considerable interest in developing AXL inhibitors to overcome tumor resistance to immunotherapy and chemotherapy. Herein, we report a novel AXL inhibitor 4j, which was discovered through structure-based drug design, SAR-driven optimization, and pharmacokinetic parameters screening. The candidate compound demonstrated excellent enzymatic activity, potent antiproliferative activity and selectivity, favorable oral bioavailability, and acceptable pharmacokinetic properties. When paired with an anti-PD-1 antibody, 4j exhibited promising therapeutic efficacy and significant synergistic effects in vivo. Taken together, 4j is an innovative therapeutic candidate for the treatment of malignant tumors.
- 3 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (23) , 34786-34807
Open AccessStructure-Based Drug Discovery of Triazine Derivatives as Potent and Orally Bioavailable AXL Inhibitors for Cancer Therapy
The receptor tyrosine kinase AXL is overexpressed in various cancers. There is considerable interest in developing AXL inhibitors to overcome tumor resistance to immunotherapy and chemotherapy. Herein, we report a novel AXL inhibitor 4j, which was discovered through structure-based drug design, SAR-driven optimization, and pharmacokinetic parameters screening. The candidate compound demonstrated excellent enzymatic activity, potent antiproliferative activity and selectivity, favorable oral bioavailability, and acceptable pharmacokinetic properties. When paired with an anti-PD-1 antibody, 4j exhibited promising therapeutic efficacy and significant synergistic effects in vivo. Taken together, 4j is an innovative therapeutic candidate for the treatment of malignant tumors.
- 9 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (10) , 4818-4836
Structure-based drug discovery of novel penta- or hexa-bicyclo-pyrazolone derivatives as potent and selective AXL inhibitors
AXL is a promising antitumor target due to its important role in tumor growth, poor survival, metastasis, immunosuppression, and drug resistance. Herein, we employed molecular modeling-assisted structural optimization strategies to design and synthesize a series of penta- or hexa-bicyclo-pyrazolone derivatives as novel AXL inhibitors. Compounds with high enzymatic and cellular potencies against AXL are described. Compound w11 showed desirable selectivity for AXL kinase, preferable pharmacokinetic properties, and excellent antitumor efficiency in the MV-4-11 xenograft model. These favorable results demonstrated that compound w11 may serve as a promising therapeutic candidate for hematological malignancy.
- 9 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (10) , 4818-4836
Structure-based drug discovery of novel penta- or hexa-bicyclo-pyrazolone derivatives as potent and selective AXL inhibitors
AXL is a promising antitumor target due to its important role in tumor growth, poor survival, metastasis, immunosuppression, and drug resistance. Herein, we employed molecular modeling-assisted structural optimization strategies to design and synthesize a series of penta- or hexa-bicyclo-pyrazolone derivatives as novel AXL inhibitors. Compounds with high enzymatic and cellular potencies against AXL are described. Compound w11 showed desirable selectivity for AXL kinase, preferable pharmacokinetic properties, and excellent antitumor efficiency in the MV-4-11 xenograft model. These favorable results demonstrated that compound w11 may serve as a promising therapeutic candidate for hematological malignancy.
- 30 January 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (3) , 856-873
Discovery of benzoheterocyclic-substituted amide derivatives as apoptosis signal-regulating kinase 1 (ASK1) inhibitors
Three series of benzoheterocyclic-substituted amide derivatives were designed and synthesized as potent ASK1 inhibitors in this work. After undergoing continuous structural optimization, compound 17a was discovered to be a novel inhibitor of ASK1 with good potency (kinase, IC50 = 26 nM), noteworthy liver microsomal stability (human, T1/2 = 340.4 min), good pharmacokinetic parameters (rat, T1/2 p.o. = 2.11 h, AUClast p.o. = 10 900 h ng mL−1) and high oral bioavailability (rat, F = 97.9%), while also being inactive towards hERG (IC50 > 10 μM).
- 30 January 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (3) , 856-873
Discovery of benzoheterocyclic-substituted amide derivatives as apoptosis signal-regulating kinase 1 (ASK1) inhibitors
Three series of benzoheterocyclic-substituted amide derivatives were designed and synthesized as potent ASK1 inhibitors in this work. After undergoing continuous structural optimization, compound 17a was discovered to be a novel inhibitor of ASK1 with good potency (kinase, IC50 = 26 nM), noteworthy liver microsomal stability (human, T1/2 = 340.4 min), good pharmacokinetic parameters (rat, T1/2 p.o. = 2.11 h, AUClast p.o. = 10 900 h ng mL−1) and high oral bioavailability (rat, F = 97.9%), while also being inactive towards hERG (IC50 > 10 μM).
- Open Access
Investigation of the Relationship between Electronic Structures and Bioactivities of Polypyridyl Ru(II) Complexes
Ruthenium (Ru)-based organometallic drugs have gained attention as chemotherapeutic and bioimaging agents due to their fewer side effects and excellent physical optical properties. Tuning the electronic structures of Ru complexes has been proven to increase the cytotoxicity of cancer cells and the luminescent efficiency of the analytical probes. However, the relationship between electronic structures and bioactivities is still unclear due to the potential enhancement of both electron donor and acceptor properties. Thus, we investigated the relationship between the electronic structures of Ru(II) complexes and cytotoxicity by optimizing the electron-withdrawing (complex 1), electron-neutral (complex 2), and electron-donating (complex 3) ligands through DFT calculations, bioactivities tests, and docking studies. Our results indicated that it was not sufficient to consider only either the effect of electron-withdrawing or electron-donating effects on biological activities instead of the total electronic effects. Furthermore, these complexes with electron-donating substituents (complex 3) featured unique “off-on” luminescent emission phenomena caused by the various “HOMO-LUMO” distributions when they interacted with DNA, while complex with electron-withdrawing substituent showed an “always-on” signature. These findings offer valuable insight into the development of bifunctional chemotherapeutic agents along with bioimaging ability.
Open AccessInvestigation of the Relationship between Electronic Structures and Bioactivities of Polypyridyl Ru(II) Complexes
Ruthenium (Ru)-based organometallic drugs have gained attention as chemotherapeutic and bioimaging agents due to their fewer side effects and excellent physical optical properties. Tuning the electronic structures of Ru complexes has been proven to increase the cytotoxicity of cancer cells and the luminescent efficiency of the analytical probes. However, the relationship between electronic structures and bioactivities is still unclear due to the potential enhancement of both electron donor and acceptor properties. Thus, we investigated the relationship between the electronic structures of Ru(II) complexes and cytotoxicity by optimizing the electron-withdrawing (complex 1), electron-neutral (complex 2), and electron-donating (complex 3) ligands through DFT calculations, bioactivities tests, and docking studies. Our results indicated that it was not sufficient to consider only either the effect of electron-withdrawing or electron-donating effects on biological activities instead of the total electronic effects. Furthermore, these complexes with electron-donating substituents (complex 3) featured unique “off-on” luminescent emission phenomena caused by the various “HOMO-LUMO” distributions when they interacted with DNA, while complex with electron-withdrawing substituent showed an “always-on” signature. These findings offer valuable insight into the development of bifunctional chemotherapeutic agents along with bioimaging ability.
- 7 March 2023
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1283
19F NMR chemical shifts are sensitive to remote functional group variations
- 7 March 2023
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1283
19F NMR chemical shifts are sensitive to remote functional group variations
- Open Access
- 3 November 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (49) , 32082-32096
Effects of fluorine bonding and nonbonding interactions on 19 F chemical shifts
19 F-NMR signals are sensitive to local electrostatic fields and are useful in probing protein structures and dynamics.
- 3 November 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (49) , 32082-32096
Open AccessEffects of fluorine bonding and nonbonding interactions on 19 F chemical shifts
19 F-NMR signals are sensitive to local electrostatic fields and are useful in probing protein structures and dynamics.
- 30 September 2022
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 51 (42) , 16224-16235
Increasing the cytotoxicity of Ru(ii) polypyridyl complexes by tuning the electron-donating ability of 1,10-phenanthroline ligands
Ruthenium (Ru)-based chemotherapeutic agents are a choice to replace traditional platinum-containing metallodrugs due to fewer side effects. It has been proved that the mechanism of Ru complex drugs is to highly likely bind with DNA and certain proteins, which also highly depends on the electronic structures of Ru complexes. However, the relationship between electronic properties and chemotherapeutic activities has not yet been completely systemically investigated, which limits the effective drug design strategies. Herein, we propose that increasing the electron densities of Ru would enhance the nucleophilic substitution rate of chlorine atoms (Cl) on Ru, providing better bioactivity against both amino acids and nucleic acids. A series of complexes with various optimized electron-donating groups (EDGs) were synthesized according to DFT calculations. In addition, kinetics substitution with L-histidine, DNA binding experiments, and cell cytotoxicity studies verified our assumptions. Surprisingly, these complexes could also be potential cellular imaging probes via an unprecedented “off–on” light-switching mechanism of living cells, which was caused by the “HOMO–LUMO” distribution changes of Ru complexes after interaction with DNA. Accordingly, the reactivity and selectivity demonstrated by these compounds support the further development of these Ru complexes in cancer treatments and afford strategic perspectives on the development of metal complexes as chemotherapeutic agents and bioimaging probes.
- 30 September 2022
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 51 (42) , 16224-16235
Increasing the cytotoxicity of Ru(ii) polypyridyl complexes by tuning the electron-donating ability of 1,10-phenanthroline ligands
Ruthenium (Ru)-based chemotherapeutic agents are a choice to replace traditional platinum-containing metallodrugs due to fewer side effects. It has been proved that the mechanism of Ru complex drugs is to highly likely bind with DNA and certain proteins, which also highly depends on the electronic structures of Ru complexes. However, the relationship between electronic properties and chemotherapeutic activities has not yet been completely systemically investigated, which limits the effective drug design strategies. Herein, we propose that increasing the electron densities of Ru would enhance the nucleophilic substitution rate of chlorine atoms (Cl) on Ru, providing better bioactivity against both amino acids and nucleic acids. A series of complexes with various optimized electron-donating groups (EDGs) were synthesized according to DFT calculations. In addition, kinetics substitution with L-histidine, DNA binding experiments, and cell cytotoxicity studies verified our assumptions. Surprisingly, these complexes could also be potential cellular imaging probes via an unprecedented “off–on” light-switching mechanism of living cells, which was caused by the “HOMO–LUMO” distribution changes of Ru complexes after interaction with DNA. Accordingly, the reactivity and selectivity demonstrated by these compounds support the further development of these Ru complexes in cancer treatments and afford strategic perspectives on the development of metal complexes as chemotherapeutic agents and bioimaging probes.
- 20 July 2022
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 13 (10) , 1246-1264
Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation
Commonly overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival, Axl has emerged as a promising target for cancer therapy. However, the availability of new chemical forms for Axl inhibition is limited. Herein, we present the development and characterization of novel Axl inhibitors, including the design, synthesis, and structure–activity relationships (SARs) of a series of diphenylpyrimidine–diamine derivatives. Most of these compounds exhibited remarkable activity against the Axl kinase. In particular, the promising compound m16 showed the highest enzymatic inhibitory potency (IC50 = 5 nM) and blocked multiple tumor cells' proliferation potencies (the CC50 of 4 out of 42 cancer cell lines m16 also possessed preferable pharmacokinetic profiles and liver microsome stability. All these favorable results make m16 a good leading therapeutic candidate for further development.
- 20 July 2022
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 13 (10) , 1246-1264
Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation
Commonly overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival, Axl has emerged as a promising target for cancer therapy. However, the availability of new chemical forms for Axl inhibition is limited. Herein, we present the development and characterization of novel Axl inhibitors, including the design, synthesis, and structure–activity relationships (SARs) of a series of diphenylpyrimidine–diamine derivatives. Most of these compounds exhibited remarkable activity against the Axl kinase. In particular, the promising compound m16 showed the highest enzymatic inhibitory potency (IC50 = 5 nM) and blocked multiple tumor cells' proliferation potencies (the CC50 of 4 out of 42 cancer cell lines m16 also possessed preferable pharmacokinetic profiles and liver microsome stability. All these favorable results make m16 a good leading therapeutic candidate for further development.